Different hypertrophic cardiomyopathy mutations were associated with varying long-term prognoses, such as 11 deaths among 15 MYH7 carriers compared to 5 deaths among 12 TNNI3 carriers.
Observational (n=46)
Do different genetic mutations in familial hypertrophic cardiomyopathy result in different long-term clinical outcomes?
Long-term clinical outcomes and prognosis in familial hypertrophic cardiomyopathy vary significantly depending on the specific causative genetic mutation.
BACKGROUND: We sought to describe the long-term outcome of individuals in 4 Korean families with hypertrophic cardiomyopathy (HCM) with known mutations. HYPOTHESIS: Long-term clinical features of familial HCM might be characterized according to the mutation causing HCM. METHODS: We performed long-term (mean, 13.1 y) clinical evaluations on 46 subjects from 4 Korean families with different mutations. RESULTS: Myosin light chain 3 gene (MYL3) mutation was associated with late-onset HCM with relatively poor prognosis; 1 sudden cardiac death and 2 cases of heart failure with atrial fibrillation occurred among 12 subjects with this mutation. Myosin binding protein C gene (MYBPC3) mutation was associated with 2 cases of sudden cardiac death and 3 cases of heart failure among 7 affected members. Cardiac troponin I type 3 gene (TNNI3) mutation was associated with 5 deaths related to atrial fibrillation and stroke among 12 mutation-positive members. Myosin heavy chain 7 gene (MYH7) mutation was associated with 11 deaths in 15 affected members. CONCLUSIONS: The clinical course was quite different for different HCM mutations. Even within the same family, individuals carrying the same mutation differed in disease expression and prognosis.
Choi et al. (Thu,) conducted a observational in Hypertrophic cardiomyopathy (n=46). Genetic mutations (MYL3, MYBPC3, TNNI3, MYH7) was evaluated on Long-term clinical outcomes (death, sudden cardiac death, heart failure). Different hypertrophic cardiomyopathy mutations were associated with varying long-term prognoses, such as 11 deaths among 15 MYH7 carriers compared to 5 deaths among 12 TNNI3 carriers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: